GLP-1 and Weight Loss Marketing Report
No corner of healthcare marketing has moved faster than GLP-1 and weight loss. Demand arrived like a gold rush, and enforcement followed close behind. This hub tracks both, quarter over quarter, and always surfaces the latest edition.
Compounded semaglutide and tirzepatide sit under drug rules, brand trademarks, and the FTC weight-loss standards at once, which is why the category draws letters that more settled verticals do not. The national telehealth brands already dominate the head terms and the AI answers. What stays winnable is local, specific, defensible intent, and the reports show where.
Latest edition · Q2 2026
GLP-1 / Weight Loss Marketing, Q2 2026: Enforcement, Search Demand, and AI Visibility
Read the Q2 2026 edition →Other reports
Healthcare Marketing and Compliance Report
The cross-vertical flagship. FDA and FTC enforcement trends alongside search demand and AI-assistant visibility across every regulated healthcare vertical we track.
TRT and Hormone Marketing Report
Hormone optimization sits next to a grey market of SARMs and compounded products. Where demand is, where the enforcement edge is, and who wins AI answers.
Medical Spa and Aesthetics Marketing Report
The most local game in aesthetics. Where med-spa demand concentrates, how product-linked claims draw letters, and how much local ground is still open.
Peptide Marketing Report
The sharpest enforcement edge in the field. Peptides live in an FDA grey zone of 503A and 503B compounding and research-use-only marketing.
Every edition is drawn from the Authoritize Atlas, our corpus of FDA and FTC actions, and from live search and AI-citation measurement. Screen your own marketing against the same rules with the free Claim Checker.